GERN vs CADL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GERN · Geron$0.99 ▲ 4.18%
CADL · Candel Therapeutics$8.75 ▲ 8.83%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GERN -14.7%
- CADL +72.6%
Head to head
| Metric | GERN | CADL |
|---|---|---|
| Price | $0.99 | $8.75 |
| Change today | ▲ 4.18% | ▲ 8.83% |
| Market cap | $637.67M | $669.54M |
| Return, 3 months | -33.1% | -16.7% |
| Return, year to date | -25.0% | +54.9% |
| Return, 1 year | -7.5% | +73.6% |
| P/E (TTM) | – | – |
| P/B | 2.8 | 5.3 |
| P/E percentile vs own 5y | 51st | 28th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +17.2% | – |
| Net profit growth (YoY) | -1.9% | -711.2% |
| Gross margin | 93.5% | – |
| Operating margin | -17.2% | – |
| Net margin | -33.1% | – |
| Return on equity | -28.3% | -81.8% |
| Analyst target vs. price | +304.1% | +145.7% |
| Analyst buy share | 75% | 100% |
| RSI (14) | 41 | 47 |
| 30-day volatility | 86.9% | 71.0% |
| Max drawdown, 1 year | -54.4% | -43.3% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CADL is the largest of the group by market value.
- CADL has returned the most over the past year.
- CADL has been the calmest stock over the last 30 days.